☆ 4.1 Letter

Placebo Controls: Now?

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2021)

Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial

Patricia R. M. Rocco et al.

Summary: In patients with mild COVID-19, there was no difference in symptom resolution between nitazoxanide and placebo groups after 5 days of treatment, but early nitazoxanide therapy significantly reduced viral load.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them

Philip R. Krause et al.

Summary: Continued follow-up of placebo recipients, use of placebo controls in large safety trials, and evaluation of clinical data from randomized trials can address important Covid-19 control needs.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal